Literature DB >> 22689869

Long-term outcomes of group B streptococcal meningitis.

Romina Libster1, Kathryn M Edwards, Fatma Levent, Morven S Edwards, Marcia A Rench, Luis A Castagnini, Timothy Cooper, Robert C Sparks, Carol J Baker, Prachi E Shah.   

Abstract

OBJECTIVE: Group B Streptococcus (GBS) is the leading cause of meningitis in young infants. We evaluated long-term outcomes among GBS meningitis survivors. We hypothesized that despite reduced mortality, GBS meningitis would remain a significant cause of morbidity among GBS survivors.
METHODS: Ninety term and near-term infants diagnosed with GBS meningitis from 1998 through 2006 were identified from 2 children's hospitals. Five died acutely, and 5 died at 6 months to 3 years of age. Forty-three survivors (54%; mean age 6.8, range 3-12 years) were consented for evaluation and underwent physical and neurologic examinations, hearing and vision screening, and standardized developmental assessments. Associations among presenting features, laboratory parameters, neurologic status at hospital discharge, and later developmental outcomes were explored by using descriptive statistics and logistic regression.
RESULTS: Twenty-four of 43 (56%) children evaluated demonstrated age-appropriate development, 11 (25%) had mild-to-moderate impairment, and 8 (19%) had severe impairment. Admission features associated with death after hospital discharge or severe impairment included lethargy (P = .003), respiratory distress (P = .022), coma or semicoma (P = .022), seizures (P = .015), bulging fontanel (P = .034), leukopenia (P = .026), acidosis (P = .024), cerebrospinal fluid protein >300 mg/dL (P = .006), cerebrospinal fluid glucose <20 mg/dL (P = .026), and need for ventilator (P = .002) or pressor support (P < .001). Features at discharge associated with late death or severe impairment included failed hearing screen (P = .004), abnormal neurologic examination (P < .001), and abnormal end of therapy brain imaging (P = .038).
CONCLUSIONS: Survivors of GBS meningitis continue to have substantial long-term morbidity, highlighting the need for ongoing developmental follow-up and prevention strategies such as maternal immunization.

Entities:  

Mesh:

Year:  2012        PMID: 22689869     DOI: 10.1542/peds.2011-3453

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  53 in total

1.  Cerebrospinal fluid procalcitonin as a biomarker of bacterial meningitis in neonates.

Authors:  Z Reshi; M Nazir; W Wani; M Malik; J Iqbal; S Wajid
Journal:  J Perinatol       Date:  2017-05-25       Impact factor: 2.521

2.  Changing Epidemiology of Group B Streptococcus Susceptibility to Fluoroquinolones and Aminoglycosides in France.

Authors:  Constantin Hays; Mathilde Louis; Céline Plainvert; Nicolas Dmytruk; Gérald Touak; Patrick Trieu-Cuot; Claire Poyart; Asmaa Tazi
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

3.  Antibody-mediated complement C3b/iC3b binding to group B Streptococcus in paired mother and baby serum samples in a refugee population on the Thailand-Myanmar border.

Authors:  Jenny Herbert; Stephen Thomas; Charlotte Brookes; Claudia Turner; Paul Turner; Francois Nosten; Kirsty Le Doare; Michael Hudson; Paul T Heath; Andrew Gorringe; Stephen Taylor
Journal:  Clin Vaccine Immunol       Date:  2015-01-14

4.  To Spinal Tap or Not To Spinal Tap, That Is the Question.

Authors:  Thomas J Lee; Paul L Aronson
Journal:  Hosp Pediatr       Date:  2018-04

5.  Immunochromatographic detection of the group B streptococcus antigen from enrichment cultures.

Authors:  Hidehito Matsui; Juri Kimura; Masato Higashide; Yoshio Takeuchi; Kuniyuki Okue; Longzhu Cui; Taiji Nakae; Keisuke Sunakawa; Hideaki Hanaki
Journal:  Clin Vaccine Immunol       Date:  2013-07-03

Review 6.  Neonatal infections: group B streptococcus.

Authors:  Paul T Heath; Luke Anthony Jardine
Journal:  BMJ Clin Evid       Date:  2014-02-28

7.  A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.

Authors:  Sharon L Hillier; Patricia Ferrieri; Morven S Edwards; Marian Ewell; Daron Ferris; Paul Fine; Vincent Carey; Leslie Meyn; Dakota Hoagland; Dennis L Kasper; Lawrence C Paoletti; Heather Hill; Carol J Baker
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

8.  Long-term sequelae of childhood bacterial meningitis.

Authors:  Lee D Hudson; Russell M Viner; Deborah Christie
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

9.  Late and very late onset group B Streptococcus sepsis: one and the same?

Authors:  Joseph B Cantey; Courtney Baldridge; Rachel Jamison; Leticia A Shanley
Journal:  World J Pediatr       Date:  2014-01-25       Impact factor: 2.764

10.  Whole-Genome Comparison Uncovers Genomic Mutations between Group B Streptococci Sampled from Infected Newborns and Their Mothers.

Authors:  Alexandre Almeida; Adrien Villain; Caroline Joubrel; Gérald Touak; Elisabeth Sauvage; Isabelle Rosinski-Chupin; Claire Poyart; Philippe Glaser
Journal:  J Bacteriol       Date:  2015-08-17       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.